Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Sharmin S, Roos I, Simpson-Yap S, Malpas C, Sánchez MM, Ozakbas S, Horakova D, Havrdova EK, Patti F, Alroughani R, Izquierdo G, Eichau S, Boz C, Zakaria M, Onofrj M, Lugaresi A, Weinstock-Guttman B, Prat A, Girard M, Duquette P, Terzi M, Amato MP, Karabudak R, Grand'Maison F, Khoury SJ, Grammond P, Lechner-Scott J, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Turkoglu R, Altintas A, Maimone D, Kermode A, Shalaby N, Pesch VV, Butler E, Sidhom Y, Gouider R, Mrabet S, Gerlach O, Soysal A, Barnett M, Kuhle J, Hughes S, Sa MJ, Hodgkinson S, Oreja-Guevara C, Ampapa R, Petersen T, Ramo-Tello C, Spitaleri D, McCombe P, Taylor B, Prevost J, Foschi M, Slee M, McGuigan C, Laureys G, Hijfte LV, de Gans K, Solaro C, Oh J, Macdonell R, Aguera-Morales E, Singhal B, Gray O, Garber J, Wijmeersch BV, Simu M, Castillo-Triviño T, Sanchez-Menoyo JL, Khurana D, Al-Asmi A, Al-Harbi T, Deri N, Fragoso Y, Lalive PH, Sinnige LGF, Shaw C, Shuey N, Csepany T, Sempere AP, Moore F, Decoo D, Willekens B, Gobbi C, Massey J, Hardy T, Parratt J, Kalincik T. Sharmin S, et al. Among authors: gobbi c. Brain. 2023 Nov 2;146(11):4633-4644. doi: 10.1093/brain/awad218. Brain. 2023. PMID: 37369086 Free PMC article.
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
Disanto G, Benkert P, Lorscheider J, Mueller S, Vehoff J, Zecca C, Ramseier S, Achtnichts L, Findling O, Nedeltchev K, Radue EW, Sprenger T, Stippich C, Derfuss T, Louvion JF, Kamm CP, Mattle HP, Lotter C, Du Pasquier R, Schluep M, Pot C, Lalive PH, Yaldizli Ö, Gobbi C, Kappos L, Kuhle J; SMSC Scientific Board. Disanto G, et al. Among authors: gobbi c. PLoS One. 2016 Mar 31;11(3):e0152347. doi: 10.1371/journal.pone.0152347. eCollection 2016. PLoS One. 2016. PMID: 27032105 Free PMC article.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
Zecca C, Merlini A, Disanto G, Rodegher M, Panicari L, Romeo MAL, Candrian U, Messina MJ, Pravatà E, Moiola L, Stefanin C, Ghezzi A, Perrone P, Patti F, Comi G, Gobbi C, Martinelli V. Zecca C, et al. Among authors: gobbi c. Mult Scler. 2018 Feb;24(2):167-174. doi: 10.1177/1352458517694089. Epub 2017 Feb 1. Mult Scler. 2018. PMID: 28273776
Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J; Swiss Multiple Sclerosis Cohort Study Group. Disanto G, et al. Among authors: gobbi c. Ann Neurol. 2017 Jun;81(6):857-870. doi: 10.1002/ana.24954. Ann Neurol. 2017. PMID: 28512753 Free PMC article.
Prodromal symptoms of multiple sclerosis in primary care.
Disanto G, Zecca C, MacLachlan S, Sacco R, Handunnetthi L, Meier UC, Simpson A, McDonald L, Rossi A, Benkert P, Kuhle J, Ramagopalan SV, Gobbi C. Disanto G, et al. Among authors: gobbi c. Ann Neurol. 2018 Jun;83(6):1162-1173. doi: 10.1002/ana.25247. Epub 2018 May 30. Ann Neurol. 2018. PMID: 29740872
60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments.
Kaufmann M, Puhan MA, Salmen A, Kamm CP, Manjaly ZM, Calabrese P, Schippling S, Müller S, Kuhle J, Pot C, Gobbi C, Steinemann N, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR). Kaufmann M, et al. Among authors: gobbi c. Front Neurol. 2020 Mar 6;11:156. doi: 10.3389/fneur.2020.00156. eCollection 2020. Front Neurol. 2020. PMID: 32210908 Free PMC article.
266 results